These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24237605)

  • 21. Variables affecting pricing of orphan drugs: the Italian case.
    Jommi C; Listorti E; Villa F; Ghislandi S; Genazzani A; Cangini A; Trotta F
    Orphanet J Rare Dis; 2021 Oct; 16(1):439. PubMed ID: 34666819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Orphan drug policies and use in pediatric nephrology.
    Karpman D; Höglund P
    Pediatr Nephrol; 2017 Jan; 32(1):1-6. PubMed ID: 27738765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High Price Medicines and Health Budgets: The Role Patients' and Consumers' Organisations Can Play.
    Houÿez F
    Eur J Health Law; 2020 May; 27(3):309-323. PubMed ID: 33652398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi.
    Hollis A
    Healthc Policy; 2019 Aug; 15(1):70-80. PubMed ID: 31629457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drugs for exceptionally rare diseases: do they deserve special status for funding?
    Hughes DA; Tunnage B; Yeo ST
    QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy.
    Roberts EA; Herder M; Hollis A
    CMAJ; 2015 Apr; 187(6):422-425. PubMed ID: 25712953
    [No Abstract]   [Full Text] [Related]  

  • 27. Analysing criteria for price and reimbursement of orphan drugs in Spain.
    Badia X; Gil A; Poveda-Andrés JL; Shepherd J; Tort M
    Farm Hosp; 2019 Jul; 43(4):121-127. PubMed ID: 31276443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
    Robinson SW; Brantley K; Liow C; Teagarden JR
    J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orphan drugs for rare diseases: is it time to revisit their special market access status?
    Simoens S; Cassiman D; Dooms M; Picavet E
    Drugs; 2012 Jul; 72(11):1437-43. PubMed ID: 22747423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey.
    Dragojlovic N; Rizzardo S; Bansback N; Mitton C; Marra CA; Lynd LD
    Patient; 2015 Feb; 8(1):93-101. PubMed ID: 25586645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An impact analysis of the implementation of health technology assessment for new treatment of orphan diseases in Japan.
    Kogushi K; Ogawa T; Ikeda S
    Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):455-471. PubMed ID: 31496361
    [No Abstract]   [Full Text] [Related]  

  • 32. [Orphan drugs and drug pirates].
    Bannenberg WJ; 't Hoen EFM
    Ned Tijdschr Geneeskd; 2020 Jun; 164():. PubMed ID: 32749801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How can the risk that orphan drugs present to budgets be managed better?
    O'Neill C
    Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
    [No Abstract]   [Full Text] [Related]  

  • 34. Orphan drugs policies: a suitable case for treatment.
    Drummond M; Towse A
    Eur J Health Econ; 2014 May; 15(4):335-40. PubMed ID: 24435513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Orphan drugs: towards an economic evaluation].
    Holué C
    Rev Prat; 2012 Jan; 62(1):91-4. PubMed ID: 22335077
    [No Abstract]   [Full Text] [Related]  

  • 36. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
    Orofino J; Soto J; Casado MA; Oyagüez I
    Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic considerations in the provision of treatments for rare diseases.
    McCabe C; Edlin R; Round J
    Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The balancing act of orphan drug pricing.
    The Lancet
    Lancet; 2017 Dec; 390(10113):2606. PubMed ID: 29256396
    [No Abstract]   [Full Text] [Related]  

  • 39. The impact of early phase price agreements on prices of orphan drugs.
    Nuijten M; Van Wilder P
    BMC Health Serv Res; 2021 Mar; 21(1):222. PubMed ID: 33711994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The rising cost of orphan drugs.
    Lancet Haematol; 2015 Nov; 2(11):e456. PubMed ID: 26686251
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.